NovaBay Pharma (NBY) Posts Q3 Break-Even EPS, 1c Better Than Estimates
More News related to NBY
- NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference
- NovaBay Pharmaceuticals Earns $3.75 Million in Milestone Payments From Galderma, S.A.
- NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum
- Alcon (ACL) Increases Financial Support to NovaBay Pharma (NBY) by $2M Per Year
- NovaBay Pharmaceuticals to Receive Increase in Funding and Support From Alcon
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) reports Q3 EPS of $0.00, 1 cent better than the analyst estimate of ($0.01). Revenue for the quarter was $1.59 million, which compares to the estimate of $2.35 million.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
